SRT3 Stock Analysis: Sartorius Aktiengesellschaft | XETRA
Medical Instruments & Supplies | XETRA, Germany | Market Cap: 16.911m EUR | 12M Return: 7.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 20.3M
EPS Trend: -52.2%
Qual. Beats: 0
Rev. Trend: -13.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sartorius Aktiengesellschaft is a German life science company that supplies bioprocess solutions, laboratory products, and services to customers worldwide. It operates a business-to-business (B2B) model, selling equipment and consumables to pharmaceutical, biotechnology, and research organizations rather than to end consumers.
Its portfolio spans several product areas. These include analytical technologies (such as surface plasmon resonance systems, biolayer interferometry, and live-cell imaging), cell culture solutions (including bioreactors, fermenters, media, reagents, and cell lines), fluid management products, and lab filtration and purification systems. The company also provides process chromatography and filtration solutions, which are commonly used in the manufacturing of biologic drugs.
Sartorius serves four main end markets: life science research, biopharmaceutical manufacturing, cell and gene therapy, and applied industries. Its bioprocessing business is closely tied to the production of biologics-drugs derived from living cells-a segment that has expanded with the growth of monoclonal antibodies, vaccines, biosimilars, and advanced therapy medicinal products.
The company was founded in 1870 and is headquartered in Göttingen, Germany. It trades on the XETRA exchange in Frankfurt under the ticker symbol SRT3 and is classified within the Health Care Equipment sub-industry of the GICS healthcare sector.
- Bioprocess orders weaken as biopharma capex contracts
- Cell and gene therapy expansion accelerates consumables demand
- China revenue declines under biosecurity legislation headwinds
| Net Income: 162.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -4.11 > 1.0 |
| NWC/Revenue: -5.34% < 20% (prev 19.69%; Δ -25.03% < -1%) |
| CFO/TA 0.07 > 3% & CFO 709.1m > Net Income 162.7m |
| Net Debt (3.93b) to EBITDA (997.3m): 3.94 < 3 |
| Current Ratio: 0.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.1m) vs 12m ago -0.34% < -2% |
| Gross Margin: 45.59% > 18% (prev 45.27%; Δ 0.32% > 0.5%) |
| Asset Turnover: 35.57% > 50% (prev 34.06%; Δ 1.51% > 0%) |
| Interest Coverage Ratio: 2.39 > 6 (EBIT TTM 574.1m / Interest Expense TTM 240.7m) |
| A: -0.02 (Total Current Assets 1.92b - Total Current Liabilities 2.11b) / Total Assets 9.87b |
| B: 0.24 (Retained Earnings 2.41b / Total Assets 9.87b) |
| C: 0.06 (EBIT TTM 574.1m / Avg Total Assets 9.99b) |
| D: 0.46 (Book Value of Equity 2.73b / Total Liabilities 5.98b) |
| Altman-Z'' = 1.53 = BB |
| DSRI: 0.94 (Receivables 366.6m/378.9m, Revenue 3.55b/3.44b) |
| GMI: 0.99 (GM 45.27% / 45.59%) |
| AQI: 1.01 (AQ_t 0.56 / AQ_t-1 0.55) |
| SGI: 1.03 (Revenue 3.55b / 3.44b) |
| TATA: -0.06 (NI 162.7m - CFO 709.1m) / TA 9.87b) |
| Beneish M = -3.06 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at EUR 242.00 with a total of 160,066 shares traded. Over the past week, the price has changed by +6.80%, over one month by +2.41%, over three months by +12.87% and over the past year by +7.45%.
Current recommended Stop Loss: 230.50 (which is 4.8% or 1.2 ATR below the current price).
Sartorius Aktiengesellschaft has no consensus analysts rating.
P/E Trailing = 103.7712
P/E Forward = 40.3226
P/S = 4.758
P/B = 5.5792
P/EG = 0.9353
Revenue TTM = 3.55b EUR
EBIT TTM = 574.1m EUR
EBITDA TTM = 997.3m EUR
Long Term Debt = 3.17b EUR (from longTermDebt, last quarter)
Short Term Debt = 963.8m EUR (from shortTermDebt, last quarter)
Debt = 4.51b EUR (from shortLongTermDebtTotal, last quarter) + Leases 204.4m
Net Debt = 3.93b EUR (calculated: Debt 4.51b - CCE 573.8m)
Enterprise Value = 20.8b EUR (16.9b + Debt 4.51b - CCE 573.8m)
Interest Coverage Ratio = 2.39 (Ebit TTM 574.1m / Interest Expense TTM 240.7m)
EV/FCF = 78.47x (Enterprise Value 20.8b / FCF TTM 265.6m)
FCF Yield = 1.27% (FCF TTM 265.6m / Enterprise Value 20.8b)
FCF Margin = 7.47% (FCF TTM 265.6m / Revenue TTM 3.55b)
Net Margin = 4.58% (Net Income TTM 162.7m / Revenue TTM 3.55b)
Gross Margin = 45.59% ((Revenue TTM 3.55b - Cost of Revenue TTM 1.93b) / Revenue TTM)
Gross Margin QoQ = 46.10% (prev 42.73%)
Tobins Q-Ratio = 2.11 (Enterprise Value 20.8b / Total Assets 9.87b)
Interest Expense / Debt = 5.34% (Interest Expense 240.7m / Debt 4.51b)
Taxrate = 31.50% (109.8m / 348.6m)
NOPAT = 393.3m (EBIT 574.1m * (1 - 31.50%))
Current Ratio = 0.91 (Total Current Assets 1.92b / Total Current Liabilities 2.11b)
Debt / Equity = 1.65 (Debt 4.51b / totalStockholderEquity, last quarter 2.73b)
Debt / EBITDA = 3.94 (Net Debt 3.93b / EBITDA 997.3m)
Debt / FCF = 14.80 (Net Debt 3.93b / FCF TTM 265.6m)
Total Stockholder Equity = 2.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.63% (Net Income 162.7m / Total Assets 9.87b)
RoE = 6.05% (Net Income TTM 162.7m / Total Stockholder Equity 2.69b)
RoCE = 9.80% (EBIT 574.1m / Capital Employed (Equity 2.69b + L.T.Debt 3.17b))
RoIC = 4.60% (NOPAT 393.3m / Invested Capital 8.55b)
WACC = 7.16% (E(16.9b)/V(21.4b) * Re(8.09%) + D(4.51b)/V(21.4b) * Rd(5.34%) * (1-Tc(0.31)))
Discount Rate = 8.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 51.85 | Cagr: 0.41%
[DCF] Terminal Value 73.10% ; FCFF base≈434.3m ; Y1≈380.8m ; Y5≈307.7m
[DCF] Fair Price = 28.94 (EV 4.94b - Net Debt 3.93b = Equity 1.01b / Shares 34.8m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -52.15 | EPS CAGR: -10.57% | SUE: -0.60 | # QB: 0
Revenue Correlation: -13.85 | Revenue CAGR: -0.65% | SUE: -0.09 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.34 | Chg30d=-0.24% | Revisions=-40% | Analysts=5
EPS next Quarter (2026-09-30): EPS=1.28 | Chg30d=-0.62% | Revisions=+40% | Analysts=5
EPS current Year (2026-12-31): EPS=5.35 | Chg30d=+0.15% | Revisions=+44% | GrowthEPS=+11.7% | GrowthRev=+6.0%
EPS next Year (2027-12-31): EPS=6.36 | Chg30d=+0.26% | Revisions=+38% | GrowthEPS=+19.0% | GrowthRev=+9.5%
[Analyst] Revisions Ratio: +39% (up=11, down=4)